Site icon pharmaceutical daily

Cell Division Cycle 7 Related Protein Kinase, Pipeline Review, H2 2019 – Lin Bioscience Inc, NMS Group SpA & Sierra Oncology Inc – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cell Division Cycle 7 Related Protein Kinase – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors.

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Metastatic Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Esophageal Cancer, Squamous Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Blood Cancer, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Leukemia, Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Rectal Cancer, Squamous Non-Small Cell Lung Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer), Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.

The latest report Cell Division Cycle 7 Related Protein Kinase – Pipeline Review, H2 2019, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

Reasons to buy

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1c5mdi

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version